• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Actelion's macitentan meets primary endpoint in phase III PAH study

Actelion's macitentan meets primary endpoint in phase III PAH study

April 30, 2012
CenterWatch Staff

Switzerland-based Actelion Pharmaceuticals' initial analysis indicates that the pivotal, long-term phase III SERAPHIN study with macitentan, a novel dual endothelin receptor antagonist, has met its primary endpoint.

In the multinational, multi-center, event-driven study, 742 patients suffering from pulmonary arterial hypertension (PAH) were treated with macitentan 3mg, 10mg or placebo for up to three and a half years. Mean exposure to study treatment was 85.3 weeks for placebo patients (n=249), 99.5 weeks for patients on 3mg (n=250) and 103.9 weeks for patients on 10mg (n=242).

Results show that macitentan, at both the 3mg and 10mg dose, decreased the risk of a morbidity/mortality event over the treatment period versus placebo. This risk was reduced by 45% in the 10mg dose group (p

Secondary efficacy endpoints, including change from baseline to month six in six-minute walk-distance, change from baseline to month six in WHO functional class and time—over the whole treatment period—to either death due to PAH or hospitalization due to PAH, also showed a dose-dependent effect (p

"I am extremely pleased with the outstanding SERAPHIN results,” said Jean-Paul Clozel, CEO of Actelion. “Submission of the registration dossier to Health Authorities worldwide is expected by the fourth quarter of 2012.”

Macitentan was well tolerated in this patient population. The number of adverse events reported and patients discontinuing treatment due to adverse events was similar across all groups. Elevations of liver alanine or aspartate aminotransferases greater than three times the upper limit of normal were observed in 4.5% of patients receiving placebo, in 3.6% of patients on 3mg of macitentan and in 3.4% of patients on 10mg of macitentan. In addition, no difference was observed between macitentan and placebo on fluid retention (edema). A decrease in hemoglobin was observed more frequently on macitentan than placebo, with no difference in treatment discontinuation between groups.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing